A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #625

Effect of Selank on Morphological Parameters of Rat Liver in Chronic Foot-Shock Stress.

Fomenko EV, Bobyntsev II, Ivanov AV, et al. Bulletin of experimental biology and medicine. 2019.
Weak / noneAnimal (in vivo)Mentions: Selank

Editor's note

In male Wistar rats subjected to chronic foot-shock stress, researchers reported that Selank, a synthetic peptide given before each stress session, reduced stress-induced liver changes. Stress caused hepatocyte swelling (hydropic degeneration), altered nucleus-to-cytoplasm ratios, focal necrosis, and immune-cell infiltration; Selank lessened these changes across doses, with the maximum stress-limiting effect at 300 micrograms/kg. The finding extends Selank's stress-protective profile to the liver. This is a single preclinical model with histological surrogate endpoints and a specific stress paradigm, and the non-linear dose response warrants caution. These are preclinical findings; human data are needed before any clinical conclusions can be drawn about Selank and stress-related liver changes.

Plain-language abstract

Researchers studied Selank, a synthetic peptide, in male rats exposed to repeated mild foot-shock stress. The stress damaged the liver, causing swollen liver cells, changes in cell structure, patches of cell death, and immune-cell buildup. Rats given Selank before each stress session had less of this damage, and the strongest protective effect came at a middle dose (300 micrograms per kilogram) rather than the highest dose. The authors conclude Selank reduced stress-related liver injury in this model. The abstract reports no adverse events. These are preclinical findings in rats; human research would be needed before drawing any conclusions about Selank's effects on the liver.